Edurant, Rekambys (rilpivirine) is a small molecule pharmaceutical. Rilpivirine was first approved as Edurant on 2011-05-20. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. Edurant's patents are valid until 2025-04-21 (FDA).
|Trade Name||Edurant, Rekambys|
|Drug Class||Antivirals: non-nucleoside reverse transcriptase inhibitors, not benzoxazinone derivatives|